KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Cash & Equivalents (2019 - 2025)

Ginkgo Bioworks Holdings' Cash & Equivalents history spans 7 years, with the latest figure at $167.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 70.23% year-over-year to $167.2 million; the TTM value through Dec 2025 reached $167.2 million, down 70.23%, while the annual FY2025 figure was $167.2 million, 70.23% down from the prior year.
  • Cash & Equivalents reached $167.2 million in Q4 2025 per DNA's latest filing, up from $111.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.7 billion in Q3 2021 to a low of $111.1 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $858.5 million, with a median of $892.3 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 483.8% in 2022, then crashed 81.98% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $1.6 billion in 2021, then fell by 15.11% to $1.3 billion in 2022, then fell by 28.25% to $944.1 million in 2023, then plummeted by 40.52% to $561.6 million in 2024, then plummeted by 70.23% to $167.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Cash & Equivalents are $167.2 million (Q4 2025), $111.1 million (Q3 2025), and $203.6 million (Q2 2025).